Project Grant R21AI196394
- Federal Grant Award Summary The Medical College of Wisconsin, Inc. received a $649,014 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 5, 2026 through January 31, 2031. The grant supports biomedical research investigating the conformation and functional dynamics of Class B penicillin-binding proteins (PBPs) in enterococcal antimicrobial resistance. This research...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $429,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 17, 2025, with completion anticipated by June 30, 2027. The award supports investigator-initiated biomedical research focused on understanding how Borrelia burgdorferi (the causative agent of Lyme disease) evades the innate...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $429,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 25, 2025, with completion targeted for May 31, 2027. This research grant funds a two-part investigation into chromatin structure and gene regulation in Anopheles coluzzii mosquitoes, a principal malaria vector species. The...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $147,486 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 30, 2025, with completion targeted for March 31, 2028. The research project, titled "Uncovering the Proviral Role of B Cell-Intrinsic STAT1 Expression During Chronic Gammaherpesvirus Infection," focuses on...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $157,884 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective December 26, 2025, through June 30, 2029. This research project investigates the effects of chromosomal inversions on gene regulation in Anopheles coluzzii mosquitoes, major malaria vectors. The research focuses on identifying and...
- Federal Grant Award Summary The Medical College of Wisconsin, Inc. received a $103,256 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective December 1, 2025, with completion anticipated by June 30, 2030. The grant supports dynamic and functional analysis of Enterococcus faecalis penicillin binding protein 4 (PBP4) pedestal domain to elucidate mechanisms underlying intrinsic...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a Project Grant award of $225,624 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 12, 2025, with a completion date of November 30, 2027. This award supports a multi-disciplinary research project investigating the role of PagC protein in bacterial outer membrane vesicle (OMV) biogenesis, with research...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $762,983 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 1, 2025 through August 31, 2026. The award funds research directed at discovering and developing novel inhibitors for human cytomegalovirus (HCMV), a pathogen that causes significant morbidity and mortality in vulnerable...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Wisconsin–Madison a $392,634 Project Grant effective May 13, 2025, through April 30, 2030, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds the development of a novel nanoimmunotherapeutic treatment approach targeting multidrug-resistant (MDR) bacterial infections, specifically gram-negative ESKAPE pathogens including...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Wisconsin–Madison a Project Grant totaling $427,625 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 1, 2026, with a completion date of January 31, 2028. This research project investigates the mechanisms of fallopian tube tissue damage caused by Neisseria gonorrhoeae infection and the resulting complications of tubal-factor...
The Medical College of Wisconsin, Inc. received a $429,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 1, 2026 through January 31, 2028. The award supports research investigating the mechanisms of Leptospira kidney colonization, specifically examining the role of bacterial clade characteristics and adhesin-mediated interactions in pathogenic leptospirosis. The research will define the functional differences among Leptospira subspecies clades in their ability to bind specific kidney cell types, including glomerular endothelial cells, podocytes, parietal epithelial cells, and proximal tubule epithelial cells, with the goal of informing the development of targeted antibacterial treatment strategies. This project addresses a significant public health need, as leptospirosis represents the most widespread zoonotic disease globally with disproportionate impacts on resource-limited populations. The research outputs will advance understanding of pathogenic leptospiral mechanisms and kidney colonization pathways, potentially enabling novel therapeutic interventions for a disease for which no human vaccines are currently approved in the United States and antibiotic treatments are effective only when administered early in infection. The work will be conducted at the awardee's Wauwatosa, Wisconsin location.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $429.0k | 2/1/26 |